title: Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice.
abstract: OBJECTIVE
  To assess the efficacy and safety profile of methotrexate (MTX) for the treatment of Crohn's disease (CD) in clinical practice.
  
  
  BACKGROUND
  MTX is widely used for some chronic immunologic diseases. Although some randomized controlled trials suggest its efficacy in CD, this drug remains a second-line, underused, immunomodulator.
  
  
  METHODS
  Medical records of all patients treated with MTX for CD in our center (n=44) were reviewed. Clinical and epidemiologic parameters, including risk factors for hepatotoxicity, were registered.
  
  
  RESULTS
  MTX was prescribed mainly for steroid-dependency (n=22) and as concomitant treatment to infliximab (n=18). Mean duration of treatment was 22.9+/-19 months, with a mean cumulative dose of MTX of 1169+/-784 mg. Thirty-nine percent of patients developed drug-related side effects, hepatotoxicity being the most frequent [13 patients (30%)]. However, only 5 patients (11%) had to discontinue MTX. In steroid-dependent CD patients, disease remission and complete steroid withdrawal was achieved in 77% of cases. Seven patients lost their initial response to MTX during follow-up, leading to a cumulative probability of remission of 39% after 3 years of treatment.
  
  
  CONCLUSIONS
  MTX is well tolerated in most CD patients. Although a great proportion of steroid-dependent CD patients achieve disease remission and steroid withdrawal, there is a trend to a loss of efficacy with time. Larger, long-term studies are necessary to establish the role of MTX in the management of CD.
authors.affiliation: Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n, Badalona, Catalonia, Spain. edomenech.germanstrias@gencat.net
authors.forename: Eugeni
authors.initials: E
authors.lastname: Domènech
authors.forename: Míriam
authors.initials: M
authors.lastname: Mañosa
authors.forename: Mercè
authors.initials: M
authors.lastname: Navarro
authors.forename: Helena
authors.initials: H
authors.lastname: Masnou
authors.forename: Esther
authors.initials: E
authors.lastname: Garcia-Planella
authors.forename: Yamile
authors.initials: Y
authors.lastname: Zabana
authors.forename: Eduard
authors.initials: E
authors.lastname: Cabré
authors.forename: Miquel A
authors.initials: MA
authors.lastname: Gassull
mesh_terms: D000293:Adolescent; D000328:Adult; D003424:Crohn Disease / Q000188:drug therapy* / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D008727:Methotrexate